Login / Signup
Gina Davis
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 4
Top Topics
Prognostic Factors
Small Cell Lung Cancer
Chemotherapy Induced
Phase Iii
Top Venues
Clinical cancer research : an official journal of the American Association for Cancer Research
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Sandra J Casak
,
Vaibhav Kumar
,
Chi Song
,
Mengdie Yuan
,
Anup K Amatya
,
Joyce Cheng
,
Pallavi S Mishra-Kalyani
,
Shenghui Tang
,
Steven J Lemery
,
Doris Auth
,
Gina Davis
,
Paul G Kluetz
,
Richard Pazdur
,
Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
(2024)
Sandra J Casak
,
Vaibhav Kumar
,
Chi Song
,
Mengdie Yuan
,
Anup K Amatya
,
Joyce Cheng
,
Pallavi S Mishra-Kalyani
,
Shenghui Tang
,
Steven J Lemery
,
Doris Auth
,
Gina Davis
,
Paul G Kluetz
,
Richard Pazdur
,
Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
30 (16) (2024)
Sandra J Casak
,
Vaibhav Kumar
,
Chi Song
,
Mengdie Yuan
,
Anup K Amatya
,
Joyce Cheng
,
Pallavi S Mishra-Kalyani
,
Shenghui Tang
,
Steven J Lemery
,
Doris Auth
,
Gina Davis
,
Paul G Kluetz
,
Richard Pazdur
,
Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
30 (16) (2024)
Sandra J Casak
,
Vaibhav Kumar
,
Chi Song
,
Mengdie Yuan
,
Anup K Amatya
,
Joyce Cheng
,
Pallavi S Mishra-Kalyani
,
Shenghui Tang
,
Steven J Lemery
,
Doris Auth
,
Gina Davis
,
Paul G Kluetz
,
Richard Pazdur
,
Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
30 (16) (2024)